Literature DB >> 12524221

Functional interplay between angiotensin II and nitric oxide: cyclic GMP as a key mediator.

Chen Yan1, Dongsoo Kim, Toru Aizawa, Bradford C Berk.   

Abstract

Angiotensin II (Ang II) and nitric oxide (NO) signaling pathways mutually regulate each other by multiple mechanisms. Ang II regulates the expression of NO synthase and NO production, whereas NO downregulates the Ang II type I (AT1) receptor. In addition, downstream effectors of Ang II and NO signaling pathways also interact with each other. A feedback mechanism between Ang II and NO is critical for normal vascular structure and function. Imbalance of Ang II and NO has been implicated in the pathophysiology of many vascular diseases. In this review, we focus on the diverse ways in which Ang II and NO interact and the importance of the balance between the signaling pathways activated by these mediators.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12524221     DOI: 10.1161/01.atv.0000046231.17365.9d

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  42 in total

Review 1.  Local renin-angiotensin systems in the genitourinary tract.

Authors:  Craig Comiter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-11-13       Impact factor: 3.000

Review 2.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

3.  Decreased cGMP level contributes to increased contraction in arteries from hypertensive rats: role of phosphodiesterase 1.

Authors:  Fernanda R Giachini; Victor V Lima; Fernando S Carneiro; Rita C Tostes; R Clinton Webb
Journal:  Hypertension       Date:  2011-01-31       Impact factor: 10.190

4.  Cyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart.

Authors:  Clint L Miller; Yujun Cai; Masayoshi Oikawa; Tamlyn Thomas; Wolfgang R Dostmann; Manuela Zaccolo; Keigi Fujiwara; Chen Yan
Journal:  Basic Res Cardiol       Date:  2011-10-20       Impact factor: 17.165

Review 5.  Sex differences in mechanisms of arterial stiffness.

Authors:  Jennifer J DuPont; Rachel M Kenney; Ayan R Patel; Iris Z Jaffe
Journal:  Br J Pharmacol       Date:  2019-05-11       Impact factor: 8.739

Review 6.  Angiotensin II receptors and peritoneal dialysis-induced peritoneal fibrosis.

Authors:  Thomas A Morinelli; Louis M Luttrell; Erik G Strungs; Michael E Ullian
Journal:  Int J Biochem Cell Biol       Date:  2016-05-07       Impact factor: 5.085

Review 7.  An update on vinpocetine: New discoveries and clinical implications.

Authors:  Yi-Shuai Zhang; Jian-Dong Li; Chen Yan
Journal:  Eur J Pharmacol       Date:  2017-11-26       Impact factor: 4.432

8.  Angiotensin II-induced aortic ring constriction is mediated by phosphatidylinositol 3-kinase/L-type calcium channel signaling pathway.

Authors:  Kee Hun Do; Min Sung Kim; Jae Ho Kim; Byung Yong Rhim; Won Suk Lee; Chi Dae Kim; Sun Sik Bae
Journal:  Exp Mol Med       Date:  2009-08-31       Impact factor: 8.718

9.  Endothelial nitric oxide synthase inhibits G12/13 and rho-kinase activated by the angiotensin II type-1 receptor: implication in vascular migration.

Authors:  Hiroyuki Suzuki; Keita Kimura; Heigoro Shirai; Kunie Eguchi; Sadaharu Higuchi; Akinari Hinoki; Kazuhiro Ishimaru; Eugen Brailoiu; Danny N Dhanasekaran; Laura N Stemmle; Timothy A Fields; Gerald D Frank; Michael V Autieri; Satoru Eguchi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-12-18       Impact factor: 8.311

10.  Diabetic nephropathy: Treatment with phosphodiesterase type 5 inhibitors.

Authors:  Cecil Stanley Thompson
Journal:  World J Diabetes       Date:  2013-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.